A new study by Univ. of California, Berkeley and Massachusetts Institute of Technology researchers finds that the practices of outsourcing and offshoring jobs appear to have both positive and negative effects on American jobs and wages. The pilot study provides the first representative and internationally comparable evidence of the domestic and international sourcing practices of U.S. private and public sector organizations.
Science and Engineering Indicators (SEI) is first and foremost a volume of record comprising the major high-quality quantitative data on the U.S. and international science and engineering enterprise. SEI is factual and policy neutral. It doesn’t offer policy options, and it doesn’t make policy recommendations.
According to a recently published biennial report from the National Science Board, the United States’ predominance in science and technology eroded further during the last decade, as several Asian nations, particularly China and South Korea, rapidly increased their innovation capacities. The study shows that while U.S. R&D rebounded from the 2008-09 recession, the traditional R&D leaders no longer monopolize global R&D.
Rice Univ. synthetic biologist Ramon Gonzalez sees a near future in which Americans get enough clean transportation fuel from natural gas to help make the nation energy independent. As a program director with the U.S. Dept. of Energy’s Advanced Research Projects Agency-Energy, he’s in a position to help make it happen.
The Salk Institute for Biological Studies will join Stanford Univ. in leading a new Center of Excellence in Stem Cell Genomics, created through a $40 million award by California's stem cell agency. The center will bring together experts and investigators from seven major California institutions to focus on bridging the fields of genomics with cutting-edge stem cell research and ultimately find new therapies.
In a Centers for Disease Control and Prevention (CDC) building on the outskirts of Atlanta, large metal vats are filled with a frozen array of specimens such as blood and DNA, many of them irreplaceable. Battelle has been awarded a five-year, $12.6 million contract to help manage this important biological repository, which contains 12 million biological samples.
The U.S. National Institutes of Health and numerous biopharmaceutical companies and disease foundations have teamed up on an unusual project to find and bring new medicines to patients faster. The Accelerating Medicines Partnership, announced Tuesday, will focus on the early part of drug research.
Do scientific papers written by well-known scholars get more attention than they otherwise would receive because of their authors’ high profiles? A new study co-authored by an Massachusetts Institute of Technology economist reports that high-status authorship does increase how frequently papers are cited in the life sciences—but finds some subtle twists in how this happens.
Congress sent President Barack Obama a $1.1 trillion government-wide spending bill Thursday, The huge bill funds every agency of government, pairing increases for NASA, the Dept. of Energy and the National Institutes of Health with cuts to the Internal Revenue Service and foreign aid. Among the things, the budget increase at NASA will allow the International Space Station to operate to at least 2024.
New data collected by the National Science Foundation have resulted in an upward revision in the previously published 2011 U.S. R&D performance total, and further expansion of U.S. R&D performance is indicated for 2012. These new data put U.S. R&D expenditures at $428.2 billion in 2011, an increase of $20.5 billion over 2010. The preliminary estimate of the 2012 U.S. total for R&D is $452.6 billion.
Innovation is improbable without proper funding, which is why R&D Magazine and Battelle Memorial Institute annually project how political developments and economic conditions around the globe will affect R&D support in the coming year. Now available, the 2014 R&D Magazine/Battelle Global R&D Funding Forecast offers a comprehensive analysis of the state of industrial research worldwide.
“Somewhere, something incredible is waiting to be known,” said astronomer Carl Sagan, who succinctly captured the essence of what it means to be a researcher. That wide-eyed sense that anything is possible through research and development, that’s the essence of a researcher’s calling.
Growth in global research and development funding slowed in 2013 from the pace of growth seen in 2011-2012. The 2013 slowdown was due primarily to unsettled European and U.S. economies that, in turn, affected global performance. R&D investments often are closely linked to GDP and economic outlook.
In the United States, R&D spending is likely to increase in 2014, turning the corner from near-zero growth in 2013. Federal funding is difficult to forecast because of the breakdown of orderly budget processes, but there are indications of bipartisan political support for increases or reallocations that favor R&D.
Federal R&D policy and implications of budget sequestration are the largest factors in funding for U.S. academic research, which has dropped from a recent high of 6% annual funding increases in 2011 to a forecast of 2% in 2014. Long recognized as an essential scientific foundation of U.S. innovation, academic research programs have been under pressure as a result.
For the past six years, the top ten countries funding R&D have remained mostly the same. There has been dramatic change, however, in the extent of globalization involved in research, as well as shifts in the way funds are spent. Driven in part by China’s aggressive programs, Southeast Asia has become the world’s largest region for research investments.
China has increased its R&D investments by 12% to 20% annually for each of the past 20 years; while at the same time, U.S. R&D spending increased at less than half those rates. As a result, China’s investment is now about 61% that of the U.S., and continuing to close.
With the large number of European Union member states, Europe’s research community is diverse in its economic composition and national interests, while central funding and administrative mechanisms allow coordinated operation of public research at a scale that is comparable to that of the United States.
As a group, the “Rest of the World” (ROW) countries—those other than the U.S., those in Europe and China—are expected to see moderate growth in their R&D investments in 2014, with leadership from countries like South Korea, Russia and Taiwan. Most Asian countries are projected to experience significant economic growth in 2014.
Research and development is a long-term investment in the future, serving as the cornerstone for innovation-driven growth. While there is a significant immediate economic impact from R&D activities, the big pay-off from investments in R&D are longer-term sustained economic gains through strengthened global competitiveness and even creation of entire new industries.
As represented in this Forecast, the life science industry includes biopharmaceuticals, medical instruments and devices, animal/agricultural bioscience and commercial research and testing. However, the industry’s R&D spending is driven primarily by the mass and research intensity of the biopharmaceutical sector, which accounts for nearly 85% of all expenditures.
The information and communications technologies (ICT) industry, and the significant level of R&D that supports it, is driven by constant change in consumer preferences, market demand and technological evolution. The ICT industry is the largest private-sector R&D investor in the U.S., performing nearly one-third of the total.
R&D among aerospace, defense and security firms is primarily driven by two sectors: the U.S. Department of Defense (DOD) and the global airline industry. The major aerospace and defense contractors plan R&D in close coordination with DOD to meet the needs of national defense and global security, while capacity, economics and efficiency are drivers for civil aviation requirements.
The energy industry includes a broad array of companies, ranging from multinational oil and gas firms to large and small technology firms. Reducing costs of production is a large driver of R&D in the energy space, and materials development and advanced materials integration are increasingly important in shaping the industry’s R&D investment.
The chemicals and advanced materials industry consists of large multinational companies serving nearly every other market, key single market material and application development firms and an array of smaller, niche chemical and material companies.